Answers are grounded in this paper and cite their sources.
Case report reveals pleural effusion linked to imatinib treatment in an elderly female, suggesting drug monitoring is essential.
Pleural effusion is a common clinical scenario, typically linked to cardiac failure, infections, or malignancies. Imatinib, a tyrosine kinase inhibitor (TKI) widely used for GIST and chronic myeloid leukemia, is known to cause fluid retention; however, significant serosal effusions are uncommon and poorly characterized. This case report highlights a rare instance of imatinib-induced pleural effusion in a 73-year-old female with recurrent gastrointestinal stromal tumor. Pleural fluid analysis was consistent with an exudative effusion. Extensive evaluation including microbiological, cytological, imaging, autoimmune and cardiac failed to identify a specific cause for effusion, prompting to consider imatinib as the most likely etiology. Additionally, she experienced recurrent effusion upon re-challenge with a reduced dose of imatinib, reinforcing the suspicion of drug-induced effusion. This case underscores the importance of maintaining a high index of suspicion for drug-related, including imatinib-induced pleural effusion, especially once the conventional causes are excluded. Proposed mechanisms include endothelial dysfunction due to PDGFR inhibition, increased vascular permeability, impaired lymphatic drainage, immune dysregulation, and renal-mediated fluid retention. Therapeutic options beyond thoracentesis and diuretics include interrupting or reducing the TKI dose and concomitant steroids.
No takes yet. Share an insight, caveat, or question.
Jacob et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: